Mease et al. Sometimes perspective is all important! We worry about apremilast causing GI effects, anorexia, weight loss. Here we see reported benefits for weight loss and HbA1c. @RheumNow #ACR25 Abstr#581 https://t.co/CJjS0VZxWH

• https://x.com/RichardPAConway/status/1982474299413049770/photo/1

Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA) Pts in remission re-randomized at wk52 Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%) Argues strongly for continuing tx in GCA for >1yr! @RheumNow #ACR25 Ab#0776 #ACRBest https://t.co/exmmIcpgbP

• https://x.com/EBRheum/status/1982473544505372756/photo/1
• https://x.com/EBRheum/status/1982473544505372756/photo/1

Damen et al. 10-year follow-up of CRESPA study. Treatment withdrawl trial in early peripheral SpA. 38% in drug free remission. 82% in remission. @RheumNow #ACR25 Abstr#568 https://t.co/KOVW5pSbJg

• https://x.com/RichardPAConway/status/1982471531679670379/photo/1

Ramiro et al. No significant differences seen between men and women in response to upadacitinib in AxSpA at week 14 or 52. Differs from data on TNFi/IL17i in this regard. Looks to me like men respond a bit quicker and better though... @RheumNow #ACR25 Abstr#589 https://t.co/2m7mrgcG0z

• https://x.com/RichardPAConway/status/1982470273321603412/photo/1

Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 🔅All patients should be on hydroxychloroquine unless with CI. ☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. #ACR25 @RheumNow https://t.co/ok5jAi7uO0

• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1
• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1

For #SLE pleuropericarditis: recommendation intentionally tries to leverage use of colchicine/NSAIDs vs. GCs But there are special situations where GCs are req’d: > Concomitant active SLE > CI to NSAIDs/Col > Recurrent pericarditis > Late pregnancy > 💊interxns #ACR25 @RheumNow https://t.co/sLL72t3Qhf

• https://x.com/RHEUMarampa/status/1982454308315484260/photo/1
• https://x.com/RHEUMarampa/status/1982454308315484260/photo/1

Year in Review: Regency Trial showed that LN pts given obinutuzumab achieved CRR at 76 wks (46.4%) vs. PBO. Take note: the Regency trial did not evaluate the extrarenal effects of Obinutuzumab in #SLE, thats for a diff study. #ACR25 @RheumNow https://t.co/WJssU1DbzZ

• https://x.com/RHEUMarampa/status/1982445925025853468/photo/1

#ACR25 New ACR Non-Renal #SLE lifecourse Guideline. 3 strong recommendations: - HCQ routinely unless contraindicated - Taper GC to =< 5mg/d - Escalate therapy in any organ system if refractory to initial therapy *Organ-specific: Conditional recommendations only @RheumNow https://t.co/w9rfcvwGHy

• https://x.com/Yuz6Yusof/status/1982455435023061266/photo/1

@ACRheum SLE Treatment Guidelines 2025 Key points: - HCQ is standard - steroids with precision - immunosuppressive therapies early - shared decision making #ACR25 @RheumNow https://t.co/AYIXE6dLlW

• https://x.com/drdavidliew/status/1982452499131871319/photo/1

🔥 Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW

• REPLENISH - Secukinumab Works in Polymyalgia Rheumatica | RheumNow
• https://x.com/DrMiniDey/status/1982143397759467619/photo/1

Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl

• https://x.com/MartinezZayasMd/status/1982147567065371058/photo/1